> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Updated Labeling for Promethazine HCl
- URL: https://www.fdaweb.com/updated-labeling-for-promethazine-hcl/
- Published: 2024-01-02T12:00:00.000Z
- Updated: 2026-09-14T14:19:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156026

FDA says it is requiring labeling updates intended to reduce the risk of severe chemical irritation and damage to tissues from intravenous administration of promethazine HCl injection. An agency [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-updates-labeling-promethazine-hydrochloride-injection-products?ref=fdaweb.com) says the injection is indicated to help manage certain allergic reactions, motion sickness, post-operative nausea, and vomiting, and as a sedative or adjunct to analgesics.

The notice says the agency recommends healthcare professionals administer promethazine HCL injection by deep intramuscular administration instead of intravenous administration. If it must be administered intravenously, it says, healthcare professionals should review and follow the updated information in the labeling to dilute the drug and administer by intravenous infusion to reduce the risk of severe tissue injury.